Clinical Trial

A Study of BG-C477 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
Protocol Amendment History 6 changes
notable Trial sites expanded: 54 -> 58 locations 2026-08-04
notable Trial sites expanded: 49 -> 52 locations 2026-06-05
notable Trial sites expanded: 41 -> 49 locations 2026-05-27
notable Trial sites expanded: 32 -> 41 locations 2026-05-12
notable Trial sites expanded: 25 -> 32 locations 2026-04-24
notable Trial sites expanded: 21 -> 25 locations 2026-04-16
Trial Details
NCT Number NCT06596473
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumors
Enrollment 310 participants
Start Date 2024-10-03
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-03